Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 73.84% | 78.69% | 32.91% | -65.52% | -18.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.84% | 78.69% | 32.91% | -65.52% | -18.59% |
| Cost of Revenue | 163.68% | -51.36% | 59.05% | -32.18% | -2.34% |
| Gross Profit | 65.56% | 110.11% | 30.52% | -66.25% | -19.82% |
| SG&A Expenses | 78.71% | 11.57% | -1.96% | -17.95% | -24.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.34% | 3.90% | 0.67% | -17.84% | -23.32% |
| Operating Income | -173.45% | 96.37% | 45.78% | -105.88% | 48.62% |
| Income Before Tax | -188.95% | 88.88% | 43.24% | -109.08% | 39.60% |
| Income Tax Expenses | -70.96% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -141.16% | 88.88% | 43.24% | -109.08% | 25.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.16% | 88.88% | 43.24% | -109.08% | 25.99% |
| EBIT | -173.45% | 96.37% | 45.78% | -105.88% | 48.62% |
| EBITDA | -178.11% | 96.85% | 46.00% | -105.41% | -- |
| EPS Basic | -112.45% | 89.07% | 44.00% | -108.89% | 27.70% |
| Normalized Basic EPS | -50.99% | 89.08% | 43.98% | -108.89% | 43.61% |
| EPS Diluted | -89.40% | 89.10% | 44.00% | -110.29% | 18.90% |
| Normalized Diluted EPS | -50.99% | 89.08% | 43.98% | -110.24% | 43.61% |
| Average Basic Shares Outstanding | 13.53% | 1.89% | 1.34% | 1.97% | 2.34% |
| Average Diluted Shares Outstanding | 13.53% | 1.89% | 1.34% | -11.43% | 2.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |